TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Nurix Therapeutics
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nurix Therapeutics will host a webcast on December 8, 2025, to present new clinical data on bexobrutideg (NX-5948), an investigational BTK degrader for treating chronic lymphocytic leukemia and Waldenström macroglobulinemia.

Insights
META   negative

Mentioned in market movers with price decline (-2.67%)


NRIX   positive

Company is presenting promising clinical trial data, expanding research into targeted protein degradation medicines, and hosting an informative webcast about their drug development progress